Tasigna, also known generically as nilotinib, is an oral therapy for individuals who've been diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia.
Patients that are no longer profiting from different therapies might be prescribed Tasigna too. Philadelphia chromosome-positive CML is a long-term, treatable type of cancer which could turn into a chronic illness if not treated correctly.
How Can Tasigna Work?
Tasigna belongs to a category of drugs called tyrosine kinase inhibitors and works by targeting and blocking tyrosine kinases, particular proteins responsible for its activation, signaling and development of particular cells.
Targeted cancer therapies like Tasigna function to prevent leukemia cells by growing while reducing the probability of harm to healthy cells. To know more about Tasigna lawsuit you can browse to Tasigna Lawsuit – Tasigna Atherosclerosis Lawsuit
Tasigna and Atherosclerosis
Tasigna was allegedly linked to atherosclerosis, a disorder where plaque builds up inside the blood vessels.
According to the National Heart, Lung, and Blood Institute, atherosclerosis may impact virtually any artery in the body, such as blood vessels in the heart, brain, arms, thighs, pelvis, and glands.
The shortage of sufficient blood flow, mainly in the legs, may possibly result in serious infections and tissue death that could occasionally require amputation.
Other Vascular Risks Connected to Tasigna
Similarly, studies have indicated a connection between Tasigna along with other tyrosine kinase inhibitors and vascular events.
Based on Haematologica, evidence indicates that nilotinib includes a propensity to raise the possibility of occlusive cardiovascular disease, particularly in patients with preexisting cardiovascular risk factors.